Goldenchook: "I kid you not. Please show me figures that refute those".
1) Nearly 20% of patients went off the medication after only 12 weeks. There is no evidence yet to suppose that number will significantly decrease.
2) Potential patient estimates derived by applying the mid-point of the published prevalence estimate range to the populations under 60 years. In other words, it's simply a prevalence estimate. There is no hard data to suggest it's accurate. Stick to known patient populations.
FWIW I tend to broadly agree with the Wilsons Equity research -which is based on reasonable assumptions not hocus pocus.
We've had some very good news the other day, and expect more good news in the near future. Be happy with that.
Don't let greed carry you away.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-108
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |